The MS Society is fully aware of Aimspro and its current use by a small number of people with MS. Despite anecdotal evidence that suggests that Aimspro is beneficial for some people, there have not yet been sufficient clinical trials to assess its safety and efficacy.

The MS Society and the UK regulatory authorities have stressed the need for Daval International (the producers of Aimspro) to undertake further clinical trials so that people with MS can have proper assurances about its possible effects.